We are live on ! Find out more
PRVB

Provention Bio, Inc. Common Stock
PRVB

Delisted

PRVB was delisted on the 26th of April, 2023.

Back to rankings

11 hedge funds and large institutions have $1.52M invested in Provention Bio, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

35% more capital invested

Capital invested by funds: $1.13M → $1.52M (+$393K)

0% more funds holding

Funds holding: 11 → 11 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

83% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 6

Holders
11
Holders Change
–
Holders Change %
0%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
6
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCP
Silverleafe Capital Partners
Tennessee
+$46.9K
2
Citadel Advisors
Citadel Advisors
Florida
+$39.6K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$1.41K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$9.41K
2
AIM
Alambic Investment Management
California
-$7.75K
3
TRCT
Tower Research Capital (TRC)
New York
-$5.3K
4
BlackRock
BlackRock
New York
-$3.75K
5
Morgan Stanley
Morgan Stanley
New York
-$2.84K

PRVB Hedge Fund Activity: Q1 2019 in Review

11 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q1 2019, worth a combined $1.52M — up 35% from $1.13M a quarter earlier.

Fund positioning in PRVB was balanced in Q1 2019: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 6 trimmed.

The largest buyer was Silverleafe Capital Partners, opening a new position worth an estimated $46.9K. The largest seller was Goldman Sachs, cutting an estimated $9.41K.

  • 11 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q1 2019, unchanged from Q4 2018.
  • Funds reported $1.52M of Provention Bio, Inc. Common Stock stock for Q1 2019, up 35% quarter-over-quarter.
  • 2 funds opened new Provention Bio, Inc. Common Stock positions in Q1 2019 and 2 closed out, a net change of 0 holders.
  • The largest Provention Bio, Inc. Common Stock buyer in Q1 2019 was Silverleafe Capital Partners, an estimated $46.9K added.
  • The largest Provention Bio, Inc. Common Stock seller in Q1 2019 was Goldman Sachs, an estimated $9.41K sold.

Based on aggregated 13F filings for Q1 2019.